A role for the terminal C5-C9 complement pathway in idiopathic pulmonary fibrosis.
bronchial lavage fluid
idiopathic pulmonary fibrosis
interstitial lung disease
proteomics
terminal complement complex
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
06
2023
accepted:
27
07
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease characterized by damage to the alveolar epithelium, leading to fibrosis and excessive accumulation of extracellular matrix in the interstitium of the lung. In the present study we performed high-resolution proteomic profiling of bronchoalveolar lavage (BAL) from IPF patients and controls, and found that the complement pathway was highly upregulated in IPF. The proteins C5, C6, C7, C8, and C9, all of which are part of the complement end product, TCC, were all upregulated. We also found that TCC levels were increased in plasma among IPF patients compared to controls, after adjustment for age, sex and BMI [mean (SD) 0.62 (0.24) vs. 0.33 (0.10),
Identifiants
pubmed: 37621463
doi: 10.3389/fmed.2023.1236495
pmc: PMC10444977
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1236495Informations de copyright
Copyright © 2023 Sikkeland, Ueland, Lund, Durheim and Mollnes.
Déclaration de conflit d'intérêts
MTD has received research funding (to his institution) and speaker/consulting fees from Boehringer Ingelheim and Roche, unrelated to the current study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Immunol. 2013 Dec 15;56(3):232-9
pubmed: 23787367
N Engl J Med. 2014 May 29;370(22):2083-92
pubmed: 24836312
Scand J Immunol. 1985 Aug;22(2):197-202
pubmed: 2412280
FASEB J. 2014 Oct;28(10):4223-34
pubmed: 24958208
Eur Respir J. 2017 Sep 11;50(3):
pubmed: 28893868
FASEB J. 2017 Dec;31(12):5543-5556
pubmed: 28821630
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552
pubmed: 34723319
Sci Rep. 2017 Apr 25;7:46560
pubmed: 28440314
Clin Immunol Immunopathol. 1990 Oct;57(1):64-73
pubmed: 2394036
N Engl J Med. 2018 May 10;378(19):1811-1823
pubmed: 29742380
Methods Mol Biol. 2017;1619:487-494
pubmed: 28674906
Am J Physiol Lung Cell Mol Physiol. 2018 Jul 1;315(1):L1-L10
pubmed: 29565179
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Int J Inflam. 2021 Oct 13;2021:3963659
pubmed: 34691383
Am J Respir Crit Care Med. 2012 May 1;185(9):1004-14
pubmed: 22550210
Eur Respir Rev. 2017 Sep 6;26(145):
pubmed: 28877976
Eur Respir J. 2021 Mar 11;57(3):
pubmed: 33154027
Eur J Clin Invest. 2018 Dec;48(12):e13028
pubmed: 30229880
FASEB J. 2016 Jun;30(6):2336-50
pubmed: 26956419
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675